VYNE Therapeutics Inc. (VYNE)
NASDAQ: VYNE · IEX Real-Time Price · USD
2.130
-0.020 (-0.93%)
At close: Jul 19, 2024, 4:30 PM
2.150
+0.020 (0.94%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
VYNE Therapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for VYNE Therapeutics stock has a target of 5.75, which predicts an increase of 169.95% from the current stock price of 2.13.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jun 14, 2024.
Analyst Ratings
According to 1 stock analyst, the rating for VYNE is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5.75 | Strong Buy | Reiterates | $5.75 | +169.95% | Jun 14, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5.75 | Strong Buy | Reiterates | $5.75 | +169.95% | Jun 5, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5.75 | Strong Buy | Reiterates | $5.75 | +169.95% | May 9, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5.75 | Strong Buy | Reiterates | $5.75 | +169.95% | May 6, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Feb 29, 2024 |
Financial Forecast
Revenue This Year
459.00K
from 424.00K
Increased by 8.25%
Revenue Next Year
n/a
from 459.00K
EPS This Year
-0.55
from -2.78
EPS Next Year
-0.81
from -0.55
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 525,000 | n/a | n/a | 21.5M | 105.5M |
| Avg | 459,000 | n/a | n/a | 10.5M | 58.2M |
| Low | 392,000 | n/a | n/a | n/a | 13.3M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 23.8% | - | - | - | 909.4% |
| Avg | 8.3% | - | - | - | 456.6% |
| Low | -7.5% | - | - | - | 27.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.10 | -0.83 | -0.74 | -10.24 | -0.16 |
| Avg | -0.55 | -0.81 | -0.71 | -9.95 | -0.15 |
| Low | -0.79 | -0.77 | -0.69 | -9.56 | -0.15 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.